Tg Therapeutics (TGTX)

$51.69 +1.43 (2.85%)
Market Cap 7.69B
Revenue (ttm) 616.29M
Net Income (ttm) 447.18M
EPS (ttm) N/A
PE Ratio 17.66
Forward PE 53.76
Profit Margin 72.56%
Debt to Equity Ratio 1.23
Volume 1,289,400
Avg Vol 2,530,454
Day's Range N/A - N/A
Shares Out 153.07M
Stochastic %K 87%
Beta 1.62
Analysts Strong Sell
Price Target $64.62

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The com...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 554 4484
Fax: 212 554 4531
Address:
3020 Carrington Mill Blvd., Suite 475, Morrisville, United States
RodneySummers1070
RodneySummers1070 Aug. 20 at 7:03 AM
$ABAT $SBET $AUTL $TGTX American Battery Technology remains focused on battery recycling and critical minerals, SBET remains highly speculative, Autolus advances engineered T-cell therapies, and TG Therapeutics benefits from its hematology portfolio. I'm watching funding, commercialization, clinical data, and prescription growth.
0 · Reply
SGL_FGHI
SGL_FGHI Aug. 20 at 6:42 AM
$TGTX -- The Bull in the viedo clip shown below is named TGTX. Its mindset and actions are what TGTX is doing to any and all that get in its way: https://www.youtube.com/shorts/_2hIAAwNLTE
0 · Reply
PennyPoacher
PennyPoacher Aug. 20 at 3:42 AM
$TGTX Alec’s new name is Cuckleberry Finn
0 · Reply
calbucs
calbucs Aug. 20 at 3:28 AM
$TGTX Still down $4 in the last 30days , making a comeback to all time highs and then through $60 . Diamond hands here
0 · Reply
Bio_investor_
Bio_investor_ Aug. 20 at 2:40 AM
$TGTX $XBI $IBB $MRNA Here is what Alec from BofA did to MRNA. He gave sell rating to MRNA 5 times in last 6 months but increasing price target by 2-4 dollars until today and then he raised $40 to $170. He is doing exactly same to TGTX despite TG is one of the fastest drug to reach blockbuster status starting next quarter and at the same time BofA is loading TGTX shares as per SEC filing. Look both table of his coverage history for both MRNA and TGTX. He intentionally pick on companies like MRNA and TGTX for personal benefit.
2 · Reply
jea1968
jea1968 Aug. 20 at 1:43 AM
$TGTX agree with previous poster…this feels like an inevitable run up to $60-65 in the short term. Going to sit back and enjoy the 20%+ run over the next 20-45 days. At $65 this is still 40% undervalued
0 · Reply
OlDocAngus
OlDocAngus Aug. 20 at 12:45 AM
$TGTX Another one to watch is this true account of Sophie Scholl. We are at the precipice of a tyrannical dictatorship and neither the Democrats OR Republicans understand the urgency of the situation. For most of them it’s business as usual…as if they are their families will escape.
0 · Reply
Quad_
Quad_ Aug. 19 at 11:44 PM
$TGTX Let's get that elusive buyout.
1 · Reply
steven1x
steven1x Aug. 19 at 11:12 PM
$TGTX not related Found a new place to eat https://youtu.be/25f33ONiKxo?is=HhdxOO7qQcWOa3YT
0 · Reply
TroyTiger
TroyTiger Aug. 19 at 10:34 PM
$TGTX except for the last 15 minutes, we had a nice day here. XBI up 2x this, but not gonna worry. Starting to spot action in $55, $60 Calls. That is where we are headed.
0 · Reply
Latest News on TGTX
TG Therapeutics price target raised to $21 from $20 at BofA

2026-08-06T14:10:41.000Z - 13 days ago

TG Therapeutics price target raised to $21 from $20 at BofA

TG Therapeutics falls -10.6%

2026-08-03T16:05:50.000Z - 16 days ago

TG Therapeutics falls -10.6%

TG Therapeutics falls -10.4%

2026-08-03T14:05:47.000Z - 16 days ago

TG Therapeutics falls -10.4%

TG Therapeutics Earnings Call Transcript: Q2 2026

Aug 3, 2026, 8:30 AM EDT - 16 days ago

TG Therapeutics Earnings Call Transcript: Q2 2026

TG Therapeutics Earnings release: Q2 2026

Aug 3, 2026, 8:30 AM EDT - 16 days ago

TG Therapeutics Earnings release: Q2 2026

TG Therapeutics Quarterly report: Q2 2026

Aug 3, 2026, 8:30 AM EDT - 16 days ago

TG Therapeutics Quarterly report: Q2 2026

TG Therapeutics raoses FY26 revenue view to $950M from $875M-$900M

2026-08-03T11:10:26.000Z - 16 days ago

TG Therapeutics raoses FY26 revenue view to $950M from $875M-$900M

TG Therapeutics reports Q2 EPS 5c, consensus 44c

2026-08-03T11:05:20.000Z - 16 days ago

TG Therapeutics reports Q2 EPS 5c, consensus 44c

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Aug 3, 2026, 7:00 AM EDT - 16 days ago

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

Jul 29, 2026, 7:30 AM EDT - 21 days ago

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

TG Therapeutics price target raised to $86 from $55 at B. Riley

2026-07-27T12:40:14.000Z - 23 days ago

TG Therapeutics price target raised to $86 from $55 at B. Riley

TG Therapeutics price target raised to $20 from $17 at BofA

2026-07-07T13:20:44.000Z - 6 weeks ago

TG Therapeutics price target raised to $20 from $17 at BofA

TG Therapeutics initiates Briumvi clinical trial

2026-07-06T11:40:36.000Z - 6 weeks ago

TG Therapeutics initiates Briumvi clinical trial

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Jul 6, 2026, 7:30 AM EDT - 6 weeks ago

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

TG Therapeutics price target raised to $83 from $57 at Jefferies

2026-06-22T20:01:38.000Z - 2 months ago

TG Therapeutics price target raised to $83 from $57 at Jefferies

TG Therapeutics Transcript: AGM 2026

Jun 11, 2026, 9:30 AM EDT - 2 months ago

TG Therapeutics Transcript: AGM 2026

TG Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 2:00 PM EDT - 2 months ago

TG Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

TG Therapeutics announces Briumvi data, initiates clinical trial

2026-06-09T11:45:09.000Z - 2 months ago

TG Therapeutics announces Briumvi data, initiates clinical trial

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Jun 9, 2026, 7:30 AM EDT - 2 months ago

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics rises 10.6%

2026-06-03T16:07:12.000Z - 2 months ago

TG Therapeutics rises 10.6%

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:40 AM EDT - 2 months ago

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

TG Therapeutics announces results from Briumvi trial

2026-06-03T12:06:50.000Z - 2 months ago

TG Therapeutics announces results from Briumvi trial

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Jun 3, 2026, 7:30 AM EDT - 2 months ago

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

Jun 2, 2026, 7:30 AM EDT - 2 months ago

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

TG Therapeutics publishes data analyses from ULTIMATE I, II studies

2026-06-01T13:23:55.000Z - 2 months ago

TG Therapeutics publishes data analyses from ULTIMATE I, II studies

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Jun 1, 2026, 7:30 AM EDT - 2 months ago

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2026, 7:30 AM EDT - 2 months ago

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TG Therapeutics reports ENHANCE trial meets primary endpoint

2026-05-27T12:20:45.000Z - 3 months ago

TG Therapeutics reports ENHANCE trial meets primary endpoint

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

May 27, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

May 26, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics reports Q1 EPS 12c, consensus 28c

2026-05-07T07:02:48.000Z - 3 months ago

TG Therapeutics reports Q1 EPS 12c, consensus 28c

TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright

2026-05-07T03:05:19.000Z - 3 months ago

TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright

TG Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

TG Therapeutics Earnings Call Transcript: Q1 2026

TG Therapeutics Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

TG Therapeutics Earnings release: Q1 2026

TG Therapeutics Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

TG Therapeutics Quarterly report: Q1 2026

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

May 6, 2026, 7:00 AM EDT - 3 months ago

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

TG Therapeutics Proxy statement: Proxy filing

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

Apr 30, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

TG Therapeutics completes enrollment in Briumvi trial

2026-04-15T11:48:15.000Z - 4 months ago

TG Therapeutics completes enrollment in Briumvi trial

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

Apr 15, 2026, 7:30 AM EDT - 4 months ago

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

TG Therapeutics secures additional $500M in non-dilutive capital

2026-03-19T12:01:33.000Z - 5 months ago

TG Therapeutics secures additional $500M in non-dilutive capital

TG Therapeutics board expands share repurchase program to $300M

2026-03-19T12:01:19.000Z - 5 months ago

TG Therapeutics board expands share repurchase program to $300M

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Mar 19, 2026, 7:30 AM EDT - 5 months ago

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Mar 9, 2026, 7:30 AM EDT - 5 months ago

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

Mar 6, 2026, 7:30 AM EST - 5 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

Mar 2, 2026, 7:01 AM EST - 6 months ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

DTIL

TG Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

TG Therapeutics Earnings Call Transcript: Q4 2025

TG Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

TG Therapeutics Annual report: Q4 2025

TG Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

TG Therapeutics Earnings release: Q4 2025

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Feb 26, 2026, 7:00 AM EST - 6 months ago

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb 23, 2026, 7:30 AM EST - 6 months ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Feb 8, 2026, 4:17 PM EST - 6 months ago

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 6, 2026, 7:30 AM EST - 6 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

These under-the-radar stocks combine fast growth with big upside potential

Jan 15, 2026, 10:31 AM EST - 7 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

TG Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:30 PM EST - 7 months ago

TG Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

TG Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:30 PM EST - 7 months ago

TG Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 8 months ago

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

TG Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 12:30 PM EST - 9 months ago

TG Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 28, 2025, 7:30 AM EST - 9 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

TG Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 10:00 AM EST - 10 months ago

TG Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

TG Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

TG Therapeutics Earnings Call Transcript: Q3 2025

TG Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

TG Therapeutics Quarterly report: Q3 2025

TG Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

TG Therapeutics Earnings release: Q3 2025

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Oct 31, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Oct 28, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Sep 24, 2025, 9:10 AM EDT - 11 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Sep 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

TG Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 10:30 AM EDT - 1 year ago

TG Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Sep 8, 2025, 7:30 AM EDT - 1 year ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

TG Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 10:20 AM EDT - 1 year ago

TG Therapeutics Transcript: Cantor Global Healthcare Conference 2025

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Sep 3, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 28, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

TG Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q2 2025

TG Therapeutics Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Quarterly report: Q2 2025

TG Therapeutics Earnings release: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings release: Q2 2025

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Aug 4, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Jul 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

TG Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 10:40 AM EDT - 1 year ago

TG Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

Jun 9, 2025, 4:51 PM EDT - 1 year ago

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

CNS LEU RMBS SFM

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 12:50 PM EDT - 1 year ago

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 27, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q1 2025

TG Therapeutics Quarterly report: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Quarterly report: Q1 2025

TG Therapeutics Earnings release: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings release: Q1 2025

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

May 5, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

TG Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Apr 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Apr 7, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Mar 7, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

Mar 4, 2025, 7:03 AM EST - 1 year ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT GILD PRVA TKO

TG Therapeutics Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q4 2024

TG Therapeutics Annual report: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Annual report: Q4 2024

TG Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings release: Q4 2024

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 27, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 26, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

TG Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

TG Therapeutics Slides: FY 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Slides: FY 2025

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

20 stocks likely to lag the S&P 500 over the next year — for this one reason

Dec 4, 2024, 7:36 AM EST - 1 year ago

20 stocks likely to lag the S&P 500 over the next year — for this one reason

CELH CENX CNXC CRSR CXM FLG GEO

TG Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

TG Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Nov 29, 2024, 8:00 AM EST - 1 year ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 21, 2024, 6:00 AM EST - 1 year ago

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

RodneySummers1070
RodneySummers1070 Aug. 20 at 7:03 AM
$ABAT $SBET $AUTL $TGTX American Battery Technology remains focused on battery recycling and critical minerals, SBET remains highly speculative, Autolus advances engineered T-cell therapies, and TG Therapeutics benefits from its hematology portfolio. I'm watching funding, commercialization, clinical data, and prescription growth.
0 · Reply
SGL_FGHI
SGL_FGHI Aug. 20 at 6:42 AM
$TGTX -- The Bull in the viedo clip shown below is named TGTX. Its mindset and actions are what TGTX is doing to any and all that get in its way: https://www.youtube.com/shorts/_2hIAAwNLTE
0 · Reply
PennyPoacher
PennyPoacher Aug. 20 at 3:42 AM
$TGTX Alec’s new name is Cuckleberry Finn
0 · Reply
calbucs
calbucs Aug. 20 at 3:28 AM
$TGTX Still down $4 in the last 30days , making a comeback to all time highs and then through $60 . Diamond hands here
0 · Reply
Bio_investor_
Bio_investor_ Aug. 20 at 2:40 AM
$TGTX $XBI $IBB $MRNA Here is what Alec from BofA did to MRNA. He gave sell rating to MRNA 5 times in last 6 months but increasing price target by 2-4 dollars until today and then he raised $40 to $170. He is doing exactly same to TGTX despite TG is one of the fastest drug to reach blockbuster status starting next quarter and at the same time BofA is loading TGTX shares as per SEC filing. Look both table of his coverage history for both MRNA and TGTX. He intentionally pick on companies like MRNA and TGTX for personal benefit.
2 · Reply
jea1968
jea1968 Aug. 20 at 1:43 AM
$TGTX agree with previous poster…this feels like an inevitable run up to $60-65 in the short term. Going to sit back and enjoy the 20%+ run over the next 20-45 days. At $65 this is still 40% undervalued
0 · Reply
OlDocAngus
OlDocAngus Aug. 20 at 12:45 AM
$TGTX Another one to watch is this true account of Sophie Scholl. We are at the precipice of a tyrannical dictatorship and neither the Democrats OR Republicans understand the urgency of the situation. For most of them it’s business as usual…as if they are their families will escape.
0 · Reply
Quad_
Quad_ Aug. 19 at 11:44 PM
$TGTX Let's get that elusive buyout.
1 · Reply
steven1x
steven1x Aug. 19 at 11:12 PM
$TGTX not related Found a new place to eat https://youtu.be/25f33ONiKxo?is=HhdxOO7qQcWOa3YT
0 · Reply
TroyTiger
TroyTiger Aug. 19 at 10:34 PM
$TGTX except for the last 15 minutes, we had a nice day here. XBI up 2x this, but not gonna worry. Starting to spot action in $55, $60 Calls. That is where we are headed.
0 · Reply
stu
stu Aug. 19 at 10:06 PM
$TGTX LOL https://x.com/semodough/status/2090143906021163192
1 · Reply
OlDocAngus
OlDocAngus Aug. 19 at 10:00 PM
$TGTX If you’ve never watched it, I encourage you to watch The Killing Fields. It’s one man’s experience escaping Cambodia after the communists overthrew the government. We are less than 5 months away from a similar scenario here in America.
1 · Reply
cbroth1
cbroth1 Aug. 19 at 9:55 PM
$TGTX most expensive TGTX shares I ever bought! Cost me another $50/share on MRNA by selling this morning! Sickening
1 · Reply
Kobe2324
Kobe2324 Aug. 19 at 9:47 PM
$TGTX couple nice buys after hours
0 · Reply
OlDocAngus
OlDocAngus Aug. 19 at 9:37 PM
$TGTX It would be a futile effort to try and warn the fools.
2 · Reply
fodness
fodness Aug. 19 at 8:23 PM
$TGTX Who thinks we get a late-breaking azer-cel abstract at ACTRIMS/ECTRIMS Toronto?
1 · Reply
Bio_investor_
Bio_investor_ Aug. 19 at 6:47 PM
$TGTX $AXSM $IBB $XBI One fine morning whoever shorted TGTX and AXSM will have same situation that MRNA shorts had today. Till then just enjoy holding or accumulating.
0 · Reply
Kobe2324
Kobe2324 Aug. 19 at 6:44 PM
$TGTX sneaky sneaky, this will be the 4th day in a row barely breaking 1 mil shares. Bring in the heavy volume and we jump to 60 in a flash. Until then we wait. I’m ok with this slow push north
1 · Reply
Frizby
Frizby Aug. 19 at 6:32 PM
$TGTX nice move on absolutely no volume. But we will take it!
0 · Reply
Bio_investor_
Bio_investor_ Aug. 19 at 6:06 PM
$TGTX $IBB $XBI Soon people will know why Mike never sold any of his 14M+ shares and only bought during open market. They trying to flush weak hand so those big players can be part of MRNA days when Sub-Q takes over the entire MS space.
0 · Reply
BillBillings
BillBillings Aug. 19 at 6:04 PM
$TGTX If Moderna truly did discover an early framework to defeat cancer, drugs that fight autoimmune and immune-mediated diseases will become more valuable m&a targets as oncology drugs now come with the additional risk of early extinction.
0 · Reply
CedarPark
CedarPark Aug. 19 at 5:22 PM
$TGTX buy more now OR miss out on 55+ going to 60. :)
0 · Reply